FibroGen's FG-4539 reduces brain tissue damage in ischemic stroke
Florida, USA-based FibroGen has said that a single dose of FG-4539, its novel small-molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) in development for the treatment of ischemic disease, was neuroprotective and significantly reduced brain tissue damage in a preclinical model of permanent ischemic stroke. The potency of FG-4539 and the window of therapeutic opportunity observed following permanent middle cerebral artery occlusion (pMCAO) compare favorably to results from this model reported for the most promising neuroprotective therapies currently in development. The data were presented on February 17 at the International Stroke Conference 2006 (Abstract number 427).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
| Headless Content Management with Blaze